Peptipedia
Weight LossIn Clinical TrialsClinical Trials

Retatrutide

Also known as LY3437943, Triple G

A triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.

Phase 3 Clinical Trials - NDA expected 2026, approval expected late 2026/early 2027
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

4-12 mg weekly

Frequency

Once weekly

Duration

Long-term use expected

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 4-12 mg weekly via Subcutaneous injection, Once weekly. Dose range: 1-12 mg weekly. Duration: Long-term use expected.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Once weekly.

Mechanism of Action

Activates three receptors: GLP-1 (appetite suppression/glucose control), GIP (enhanced insulin response/metabolic effects), and glucagon (increased energy expenditure/fat oxidation) with synergistic effects.

Research Summary

Evidence level: clinical trials. Clinical status: Phase 3 Clinical Trials - NDA expected 2026, approval expected late 2026/early 2027.

Side Effects & Safety

Important Warnings

  • Phase 3 TRIUMPH-4: 28.7% weight loss at 68 weeks
Nausea (dose-related)
diarrhea
vomiting
constipation
heart rate increases
hypersensitivity reactions
dysesthesia (~21% at highest dose)
pancreatitis

References

No references available.

Related Peptides

Browse all →
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile
TirzepatideWeight Loss

A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.

View profile
SurvodutideWeight Loss

A dual GLP-1/glucagon receptor agonist being developed for obesity and metabolic dysfunction-associated fatty liver disease (MASH). Phase 2 showed 83% MASH resolution vs 18% placebo.

View profile